Through this partnership, Sagent will gain sole rights to commercialise a select portfolio of Qilu’s complex injectable products in the US. These products encompass high-impact therapeutic areas,
This recommendation paves the way for a new therapy option for adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at high risk
The acquisition bolsters AscellaHealth’s capabilities to serve international manufacturers and patients in more than 70 countries across the EU, Asia, Africa, Australia and the Americas. CHAPPER healthcare is
This collaboration is pivotal as GBS remains a significant cause of severe infections in newborns, accounting for nearly half of all life-threatening cases. With 15-25% of the population,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.